Irene L. Katzan

Irene L. Katzan

Auto-generated profile, based on publicly available information

Irene L. Katzan

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in JAMA
Verified
Journal Article
Open access
PDF file
IKIrene L. Katzan
Irene L. Katzan
AFAnthony J. Furlan
Anthony J. Furlan
LLLynne E. Lloyd
Lynne E. Lloyd
JFJeffrey I. Frank
Jeffrey I. Frank
DHDwain L. Harper
Dwain L. Harper
CSCathy A. Sila
Cathy A. Sila
Research from JAMA — Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke — The Cleveland Area Experience — ContextLittle is known regarding outcomes after intravenous tissue-type plasminogen activator (IV tPA) therapy for acute ischemic stroke outside a trial setting.ObjectiveTo assess the rate of IV tPA use, the incidence of symptomatic intracerebral hemorrhage (ICH), and in-hospital patient outcomes throughout a large urban community.DesignHistorical prospective cohort study conducted from July 1997 through June 1998.SettingTwenty-nine hospitals in the Cleveland, Ohio, metropolitan area.PatientsA total of 3948 patients admitted to a study hospital with a primary diagnosis of ischemic stroke (International Classification of Diseases, Ninth Revision, Clinical Modification code 434 or 436).Main Outcome MeasuresRate of IV tPA use and occurrence of symptomatic ICH among patients treated with tPA; proportion of patients receiving tPA whose treatment deviated from national guidelines; in-hospital mortality among patients receiving tPA compared with that among ischemic stroke patients not receiving tPA and with mortality predicted by a model.ResultsSeventy patients (1.8%) admitted with ischemic stroke received IV tPA. Of those, 11 patients (15.7%; 95% confidence interval [CI], 8.1%-26.4%) had a symptomatic ICH (of which 6 were fatal) and 50% (95% CI, 37.8%-62.2%) had deviations from national treatment guidelines. In-hospital mortality was significantly higher among patients treated with tPA (15.7%) compared with patients not receiving tPA (5.1%, P<.001) and compared with the model's prediction (7.9%; P<.006).ConclusionsA small proportion of patients admitted with acute ischemic stroke in Cleveland received tPA; they experienced a high rate of ICH. Cleveland community experience with tPA for acute ischemic stroke may differ from that reported in clinical trials.

1 March 2004 in Archives of Neurology
Verified
Journal Article
Closed access
PDF file
IKIrene L. Katzan
Irene L. Katzan
MHMaxim D. Hammer
Maxim D. Hammer
EHEric D. Hixson
Eric D. Hixson
AFAnthony J. Furlan
Anthony J. Furlan
AAAlex Abou-Chebl
Alex Abou-Chebl
DNDeborah M. Nadzam
Deborah M. Nadzam
Research from JAMA Neurology — Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke

1 March 2003 in Stroke
Verified
Journal Article
Closed access
PDF file
IKIrene L. Katzan
Irene L. Katzan
MHMaxim D. Hammer
Maxim D. Hammer
AFAnthony J. Furlan
Anthony J. Furlan
EHEric D. Hixson
Eric D. Hixson
DNDeborah M. Nadzam
Deborah M. Nadzam
Background and Purpose— A systematic audit of intravenous tissue-type plasminogen activator (tPA) use and stroke outcomes in Cleveland, Ohio, during 1997–1998 demonstrated higher rates of symptomatic intracranial hemorrhage (ICH) than reported in the National Institute of Neurological Disorders and Stroke (NINDS) trial. We now report updated results of intravenous tPA use in the Cleveland Clinic Health System (CCHS). Methods— A stroke quality improvement program was initiated in the 9-hospital CCHS in 1999. A retrospective chart review for all stroke patients with primary International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes 434 and 436 admitted to the 9 hospitals from June 1999 to June 2000 was used to determine outcomes of patients treated with intravenous tPA. Results— Intravenous tPA was given to 18.8% of patients arriving within 3 hours of symptom onset. Protocol deviations occurred in 19.1% of patients given intravenous tPA. The symptomatic ICH rate was 6.4%. Conclusions— Since 1997, intravenous tPA use has increased, while the rates of symptomatic ICH and protocol deviations have decreased in the CCHS. The CCHS symptomatic ICH rate is now similar to that reported in the NINDS trial. These improvements occurred after initiation of a stroke quality improvement program.

1 January 2018 in Stroke
Verified
Journal Article
Closed access
PDF file
IKIrene L. Katzan
Irene L. Katzan
BLBrittany Lapin
Brittany Lapin
Background and Purpose—: The International Consortium for Health Outcomes Measurement recently included the 10-item PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) scale as part of their recommended Standard Set of Stroke Outcome Measures. Before collection of PROMIS GH is broadly implemented, it is necessary to assess its performance in the stroke population. The objective of this study was to evaluate the psychometric properties of PROMIS GH in patients with ischemic stroke and intracerebral hemorrhage. Methods—: PROMIS GH and 6 PROMIS domain scales measuring same/similar constructs were electronically collected on 1102 patients with ischemic and hemorrhagic strokes at various stages of recovery from their stroke who were seen in a cerebrovascular clinic from October 12, 2015, through June 2, 2017. Confirmatory factor analysis was performed to evaluate the adequacy of 2-factor structure of component scores. Test–retest reliability and convergent validity of PROMIS GH items and component scores were assessed. Discriminant validity and responsiveness were compared between PROMIS GH and PROMIS domain scales measuring the same or related constructs. Analyses were repeated stratified by stroke subtype and modified Rankin Scale score <2 versus ≥2. Results—: There was moderate internal reliability (ordinal α, 0.82–0.88) and marginal model fit for the 2-factor solution for component scores (root mean square error of approximation, 0.11). Convergent validity was good with significant correlations between all PROMIS GH items and PROMIS domain scales ( P 0.5) was demonstrated for 8 of the 10 PROMIS GH items. Reliability and validity remained consistent across stroke subtype and disability level (modified Rankin Scale, <2 versus ≥2). Conclusions—: PROMIS GH exhibits acceptable performance in patients with stroke. Our findings support International Consortium for Health Outcomes Measurement recommendation to use PROMIS GH as part of the standard set of outcome measures in stroke.

17 April 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
IKIrene L. Katzan
Irene L. Katzan
NTNicolas R. Thompson
Nicolas R. Thompson
KUKen Uchino
Ken Uchino
BLBrittany Lapin
Brittany Lapin
Objectives (1) Examine 8 patient-reported domains of health across levels of disability compared to the US general population; and (2) identify factors associated with domain scores in patients with ischemic stroke. Methods Observational cohort study of 1,195 patients in a cerebrovascular clinic from February 17, 2015, to January 27, 2017, who completed Neuro-QoL (Quality of Life in Neurological Disorders) executive function or the following PROMIS (Patient-Reported Outcomes Measurement Information System) scales as part of routine care: physical function, satisfaction with social roles, fatigue, anxiety, depression, pain interference, and sleep disturbance. Results Mean age was 62 (±15) years, and 81% were white. Median modified Rankin Scale (mRS) score at the clinic visit was 1 (interquartile range 0–2). Percentage of patients with scores meaningfully worse than the general population ranged from 28% (sleep disturbance) to 63% (physical function). Scores were worse in patients with higher mRS levels, although correlation between scores and mRS level varied (sleep disturbance r = 0.16 to physical function r = 0.52). Most affected domains were physical function (T score = 58.8), satisfaction with social roles (T score = 55.4), and executive function (T score = 53.4). Disability, lower income, and female sex were associated with worse scores in multiple domains. Age was associated with worse physical function but lower anxiety, depression, and sleep disturbance. Conclusions Patients with ischemic stroke reported symptoms in multiple domains that increase to variable degrees at higher levels of disability. Physical function, satisfaction with social roles, and executive function were most affected. This information improves our understanding of the well-being of patients with ischemic stroke and brings attention to the importance of social roles and executive function for stroke survivors.

1 July 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
IKIrene L. Katzan
Irene L. Katzan
NTNicolas R. Thompson
Nicolas R. Thompson
BLBrittany Lapin
Brittany Lapin
KUKen Uchino
Ken Uchino
Background: There is uncertainty regarding the clinical utility of the data obtained from patient‐reported outcome measures ( PROM s) for patient care. We evaluated the incremental information obtained by PROM s compared to the clinician‐reported modified Rankin Scale ( mRS ). Methods and Results: This was an observational study of 3283 ischemic stroke patients seen in a cerebrovascular clinic from September 14, 2012 to June 16, 2015 who completed the routinely collected PROM s: Stroke Impact Scale‐16 ( SIS ‐16), EQ ‐5D, Patient Health Questionnaire‐9, PROMIS Physical Function, and PROMIS fatigue. The amount of variation in the PROM s explained by mRS was determined using r 2 after adjustment for age and level of stroke impairment. The proportion with meaningful change was calculated for patients with ≥2 visits. Concordance with change in the other scales and the ability to discriminate changes in health state as measured by c‐statistic was evaluated for mRS versus SIS ‐16. Correlation between PROM s and mRS was highest for SIS ‐16 ( r =−0.64, P <0.01). The r 2 ranged from 0.11 ( PROMIS fatigue) to 0.56 ( SIS ‐16). Change in scores occurred in 51% with mRS and 35% with SIS ‐16. There was lower agreement and less ability to discriminate change in mRS than in SIS ‐16 with change in the other measures. Conclusions: PROM s provide additional valuable information compared to the mRS alone in stroke patients seen in the ambulatory setting. SIS ‐16 may have a better ability to identify change than mRS in health status of relevance to the patient. PROM s may be a useful addition to mRS in the assessment of health status in clinical practice.